Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 12/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140569 | 0.85 | PIK3CG (0.50) | DYRK1AITKPIK3CG | |
| SCHEMBL144539 | 0.84 | MAPT (0.55) | DYRK1ALCKITKAURKB | |
| SCHEMBL140232 | 0.77 | ITK (0.69) | DYRK1ACSNK1DLCKITKAURKB | |
| SCHEMBL140233 | 0.77 | ITK (0.69) | DYRK1ACSNK1DLCKITKAURKB | |
| SCHEMBL143889 | 0.75 | LCK (0.49) | DYRK1ALCKITKAURKB | |
| SCHEMBL141486 | 0.75 | LCK (0.67) | LCKITKAURKB | |
| SCHEMBL138887 | 0.73 | RAB9A (0.52) | LCKITKAURKBPIK3CG | |
| SCHEMBL140313 | 0.73 | LCK (0.55) | CSNK1DLCKITKAURKB | |
| SCHEMBL138176 | 0.73 | LCK (0.55) | DYRK1ACSNK1DLCKITKAURKB | |
| SCHEMBL5683714 | 0.73 | DYRK1A (0.68) | DYRK1ACSNK1DCYP2D6ACP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | DYRK1A 591/4885CSNK1D 437/4885LCK 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.